Birds's Eye
Technicals
MovingAverage
Candlestick
PivotPoint
Fin Statements
Beta&Vols
Tech Charts
Future/OptionFundamental Analysis of Piramal Pharma Ltd. - Growth / Value Index
PPLPHARMA - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.786
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Price to Earning | 248.04 | 325.72 | -64.62 % | ||
| Price to Book | 3.04 | 3.65 | 76.15 % | 2.97 | |
| Price to Sales | 2.66 | 3.24 | 61.54 % | ||
| Enterprise Value to EBITDA Multiple | 21.57 | 37.60 % |
PPLPHARMA - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Tsr Profitability Index - Poor Score of 23.75
Very Low Dividend Yield of 0 %
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
EPS decline for last four quarters
Negative Net Margin MRQ
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Return On Equity | 1.23 | 1.12 | 397.92 % | -1.01 | |
| Return On Asset | 0.636 | 0.581 | 399.46 % | -0.521 | |
| Net Profit Margin | 1.07 | 0.996 | 356.63 % | -4.23 | |
| Operating Profit Margin | 54.48 | 2.26 | 2465.87 % | 5.52 | |
| EBITDA Margin | 17.63 | 17.26 | 7.76 % | 10.57 |
Highlights
| Market Cap | 242448 M |
| Enterprise Value | 286332 M |
| Price/Book TTM | 3.04 |
| Outstanding Share | 1321.68 M |
| Float/ Outstanding Share | 45.33% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 5.73 |
| Peter Lynch Ratio | 1.58 |
| Piotroski F Score | 7.00 |
| Altman Z Score | 2.92 |
| Sloan Ratio | -0.0206 |
| Peter Lynch Fair Value | 0 |
PPLPHARMA - Growth Highlights
Growth Analysis
Tremendous increasing trend in total sale last 3 year
YoY Net Margin Jump by 356.63%
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Very Poor Score of 14.58
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 9133.75 (Cr) | 11.99 % | 29.79 % |
| Gross Profit | 5130.67 (Cr) | 141.90 % | 31.10 % |
| EBITDA | 1610.55 (Cr) | 20.69 % | 66.99 % |
| Net Profit | 98.07 (Cr) | 411.39 % | 153.22 % |
| EPS | 0.740 | 392.86 % | NA |
PPLPHARMA - Stability Highlights
Stability Analysis
Company financial liquidity has improved
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|
| Debt to Equity Ratio | 0.585 | 0.866 % | 0.585 | |
| Cash Ratio | 0.133 | 20.56 % | ||
| Quick Ratio | 0.925 | 22.92 % | 0.925 | |
| Shareholders Equity | 51.83 | 0.310 % | ||
| Debt to EBITDA | 3.01 | -14.16 % |
Historical Valuation Ratios of Piramal Pharma Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Piramal Pharma Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Piramal Pharma Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Piramal Pharma Ltd.
Historical Solvency Ratios
Loading ...